Stephen F.  Betz net worth and biography

Stephen Betz Biography and Net Worth

Stephen F. Betz, Ph.D., is a co-founder of Crinetics and was Vice President of Biology from December 2009 to October 2021 and currently serves as our Chief Scientific Officer. In addition, Dr. Betz is a member of the scientific advisory board of Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications.

Earlier in his career, Dr. Betz was Director of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, from 2001 to 2003, he led laboratory efforts at GeneFormatics, Inc., and from 1996 to 2000, he worked in pharmaceutical discovery at Abbott Laboratories, including structure-guided drug design, assay development, and compound screening in the Research Nuclear Magnetic Resonance Group.

What is Stephen F. Betz's net worth?

The estimated net worth of Stephen F. Betz is at least $3.26 million as of January 25th, 2024. Dr. Betz owns 73,298 shares of Crinetics Pharmaceuticals stock worth more than $3,256,630 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Betz may own. Additionally, Dr. Betz receives an annual salary of $618,580.00 as Insider at Crinetics Pharmaceuticals. Learn More about Stephen F. Betz's net worth.

How old is Stephen F. Betz?

Dr. Betz is currently 58 years old. There are 5 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. Dana Pizzuti M.D., Chief Development Officer, who is 68 years old. Learn More on Stephen F. Betz's age.

What is Stephen F. Betz's salary?

As the Insider of Crinetics Pharmaceuticals, Inc., Dr. Betz earns $618,580.00 per year. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $870,690.00 per year. Learn More on Stephen F. Betz's salary.

How do I contact Stephen F. Betz?

The corporate mailing address for Dr. Betz and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Stephen F. Betz's contact information.

Has Stephen F. Betz been buying or selling shares of Crinetics Pharmaceuticals?

In the last ninety days, Stephen F. Betz has sold $224,730.00 in Crinetics Pharmaceuticals stock. Most recently, Stephen F. Betz sold 3,000 shares of the business's stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $37.26, for a transaction totalling $111,780.00. Following the completion of the sale, the insider now directly owns 73,298 shares of the company's stock, valued at $2,731,083.48. Learn More on Stephen F. Betz's trading history.

Who are Crinetics Pharmaceuticals' active insiders?

Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), Ajay Madan (Insider), and Richard Struthers (CEO). Learn More on Crinetics Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Crinetics Pharmaceuticals?

During the last year, Crinetics Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $110,300.00. During the last year, insiders at the sold shares 20 times. They sold a total of 507,105 shares worth more than $15,911,839.93. The most recent insider tranaction occured on March, 22nd when COO Jeff E Knight sold 32,359 shares worth more than $1,433,827.29. Insiders at Crinetics Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.

Information on this page was last updated on 3/22/2024.

Stephen F. Betz Insider Trading History at Crinetics Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2024Sell3,000$37.26$111,780.0073,298View SEC Filing Icon  
1/10/2024Sell3,000$37.65$112,950.0076,298View SEC Filing Icon  
12/26/2023Sell3,000$35.89$107,670.0079,298View SEC Filing Icon  
12/11/2023Sell3,000$32.87$98,610.0082,298View SEC Filing Icon  
11/27/2023Sell3,000$31.84$95,520.0085,298View SEC Filing Icon  
1/25/2023Sell8,336$21.07$175,639.5267,815View SEC Filing Icon  
1/17/2023Sell3,126$18.00$56,268.0076,151View SEC Filing Icon  
12/15/2022Sell3,126$16.00$50,016.0082,403View SEC Filing Icon  
12/1/2022Sell3,126$17.84$55,767.8484,968View SEC Filing Icon  
11/15/2022Sell3,126$18.72$58,518.7288,094View SEC Filing Icon  
10/17/2022Sell3,126$17.73$55,423.9894,346View SEC Filing Icon  
10/3/2022Sell3,126$19.64$61,394.6497,472View SEC Filing Icon  
9/15/2022Sell4,168$21.01$87,569.68100,598View SEC Filing Icon  
9/7/2022Sell1,042$21.00$21,882.00104,766View SEC Filing Icon  
5/2/2022Sell3,247$20.10$65,264.70107,598View SEC Filing Icon  
4/18/2022Sell5,664$25.81$146,187.84110,845View SEC Filing Icon  
4/4/2022Sell9,000$23.97$215,730.00116,509View SEC Filing Icon  
3/31/2022Sell4,164$21.06$87,693.84View SEC Filing Icon  
3/1/2022Sell3,123$19.73$61,616.79View SEC Filing Icon  
2/1/2022Sell3,123$18.79$58,681.17View SEC Filing Icon  
1/18/2022Sell4,168$23.29$97,072.72View SEC Filing Icon  
1/3/2022Sell7,168$28.02$200,847.36View SEC Filing Icon  
12/28/2021Sell3,000$27.95$83,850.00View SEC Filing Icon  
12/15/2021Sell5,668$24.14$136,825.52View SEC Filing Icon  
12/1/2021Sell5,668$27.38$155,189.84View SEC Filing Icon  
11/8/2021Sell3,900$28.42$110,838.00View SEC Filing Icon  
11/5/2021Sell12,600$27.95$352,170.00View SEC Filing Icon  
11/1/2021Sell5,668$24.79$140,509.72View SEC Filing Icon  
10/27/2021Sell3,000$24.00$72,000.00View SEC Filing Icon  
10/21/2021Sell1,042$21.10$21,986.20View SEC Filing Icon  
See Full Table

Stephen F. Betz Buying and Selling Activity at Crinetics Pharmaceuticals

This chart shows Stephen F Betz's buying and selling at Crinetics Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $44.43
Low: $43.10
High: $44.64

50 Day Range

MA: $39.56
Low: $35.50
High: $46.03

2 Week Range

Now: $44.43
Low: $15.23
High: $47.58

Volume

836,861 shs

Average Volume

751,373 shs

Market Capitalization

$3.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62